G
G. Schuch
Researcher at Praxis
Publications - 8
Citations - 1319
G. Schuch is an academic researcher from Praxis. The author has contributed to research in topics: Bevacizumab & Irinotecan. The author has an hindex of 4, co-authored 8 publications receiving 673 citations.
Papers
More filters
Journal ArticleDOI
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Thorsten Oliver Goetze,Johannes Meiler,Stefan Kasper,Hans-Georg Kopp,Frank Mayer,Georg Martin Haag,Kim Barbara Luley,U. Lindig,Wolff Schmiegel,Michael Pohl,Jan Stoehlmacher,Gunnar Folprecht,Stephan Probst,Nicole Prasnikar,Wolfgang Fischbach,Rolf Mahlberg,Jörg Trojan,Michael Koenigsmann,Uwe M. Martens,Peter C. Thuss-Patience,Matthias Egger,Andreas Block,Volker Heinemann,Gerald Illerhaus,Markus Moehler,Michael Schenk,Frank Kullmann,Dirk M Behringer,Michael Heike,Daniel Pink,Christian Teschendorf,Carmen Löhr,Helga Bernhard,G. Schuch,Volker Rethwisch,Ludwig Fischer von Weikersthal,Jörg T. Hartmann,Michael Kneba,Severin Daum,Karsten Schulmann,Jörg Weniger,Sebastian Belle,Timo Gaiser,Fuat Oduncu,Martina Güntner,Wael Hozaeel,Alexander Reichart,Elke Jäger,Thomas Kraus,Stefan Mönig,Wolf O. Bechstein,Martin Schuler,Harald Schmalenberg,Ralf Hofheinz,Flot Aio Investigators +57 more
TL;DR: In this article, the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin, and doceteaxel) as a perioperative therapy for patients with locally advanced, resectable tumours was reported.
Journal ArticleDOI
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Dominik Paul Modest,Ludwig Fischer von Weikersthal,Thomas Decker,Ursula Vehling-Kaiser,Jens Uhlig,Michael Schenk,J. Freiberg-Richter,Bettina Peuser,Claudio Denzlinger,Christina Peveling genannt Reddemann,Ullrich Graeven,G. Schuch,Ingo Schwaner,Arndt Stahler,Andreas Jung,Thomas Kirchner,Swantje Held,Sebastian Stintzing,Clemens Giessen-Jung,Volker Heinemann,Xelaviri,Aio Krk Investigators +21 more
TL;DR: Noninferiority of sequential escalation therapy compared with initial combination chemotherapy could not be demonstrated for TFS, whereas sequential escalation chemotherapy seems to provide comparable results in patients with RAS mutant tumors.
Journal ArticleDOI
A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)
Salah-Eddin Al-Batran,Joerg T. Hartmann,Stephan Probst,R.D. Hofheinz,Jan Stoehlmacher,Harald Schmalenberg,S. Hollerbach,G. Schuch,Nils Homann,Elke Jäger +9 more
TL;DR: Cisplatin-based chemotherapy is a standard option in advanced gastric cancer, but treatment results have been unsatisfactory so far, with a time to progression (TTP) of 3 years.
Journal ArticleDOI
3502 ORAL Final results of a randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)
Salah-Eddin Al-Batran,J.T. Hartmann,Stephan Probst,R.D. Hofheinz,Jan Stoehlmacher,Claudia Pauligk,S. Hollerbach,G. Schuch,N. Homann,Elke Jäger +9 more
TL;DR: FLO reduced toxicity and improved efficacy as compared to FLP and was associated with significantly less NCI-CTC grade 1-4 leukopenia, nausea, alopecia, fatigue, and renal toxicity.
Journal ArticleDOI
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry
Salah-Eddin Al-Batran,Ralf-Dieter Hofheinz,Alexander Reichart,Claudia Pauligk,Caroline Schönherr,Rudolf Schlag,Gabriele Margareta Siegler,Steffen Dörfel,Michael Koenigsmann,Mark-Oliver Zahn,Jörg Schubert,Ali Aldaoud,Heinz-Gert Höffkes,Holger Schulz,Lars Hahn,Jens Uhlig,Wolfgang Blau,Martina Stauch,Jörg Weniger,Martin Wolf,Lutz Jacobasch,Stephan Bildat,Jürgen Wehmeyer,Nils Homann,Jörg Trojan,Oliver Waidmann,Thomas Fietz,Hans-Peter Feustel,Matthias Groschek,Jan Wierecky,Karin Waibel,Stefan Mahlmann,Uwe Schwindel,U. R. Peters,G. Schuch,Daniel Pink,Henning Eschenburg,Marcus-A Wörns,Hans-Detlev Harich,Ludwig Fischer von Weikersthal,Klaus-Ulrich Däßler,Dirk Behringer,Helmut Messmann,Albrecht Kretzschmar,Eike Gallmeier,Helmut Forstbauer,Volker Kunzmann,Jens Papke,Petra Büchner-Steudel,Ursula Vehling-Kaiser,Christoph Springfeld,Arndt Vogel,Thomas J. Ettrich,Marina Schaaf,Gerrit zur Hausen,Thorsten Oliver Götze,Arbeitsgemeinschaft Internistische Onkologie +56 more
TL;DR: The QOLIXANE study is a prospective, noninterventional, multicenter substudy of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with mPC receiving first‐line gemcitabine and nab‐paclitaxel chemotherapy in real‐life setting.